# Comparing the efficacy and safety of safinamide with rasagiline in China Parkinson’s disease patients with a matching adjusted indirect comparison

## TL;DR

This study compares safinamide and rasagiline for Parkinson's disease in China, finding safinamide more effective in reducing motor fluctuations without safety issues.

## Contribution

The study provides a novel comparison of safinamide and rasagiline in Chinese PD patients using a matching-adjusted indirect comparison method.

## Key findings

- Safinamide reduced daily OFF time by 0.7 hours more than rasagiline.
- Safinamide showed greater improvement in UPDRS III scores compared to rasagiline.
- No significant differences in safety outcomes between the two drugs were observed.

## Abstract

Safinamide and rasagiline are adjuncts to levodopa for the motor fluctuations of Parkinson’s Disease (PD). However, there remains a scarcity of head-to-head studies that directly compare safinamide and rasagiline. This study compared safinamide and rasagiline as adjuncts to levodopa in Chinese PD patients with motor fluctuations by matching-adjusted indirect comparison. Baseline age, sex, BMI, and OFF time were adjusted for matching. Efficacy outcomes were the mean changes in total daily OFF time, UPDRS III, and PDQ-39 from baseline to week 16, which calculated by a weighted covariance model. Safety outcomes included rates of AEs, SAEs, and DCAEs. Bucher method was used for mean difference (MD) of efficacy and odds ratio (OR) of safety outcomes. Combination therapy of safinamide 50-100 mg/day and levodopa significantly reduced the mean total daily OFF time by 0.7 h (− 1.40 to − 0.02) compared to the combination therapy of rasagiline 1 mg/day and levodopa. Safinamide more effectively reduced UPDRS III (− 2.9, − 5.28 to − 0.52). Changes in PDQ-39 scores indicated a trend toward greater improvement in safinamide. There was no significant difference in safety outcomes. Compared to rasagiline, the combined therapy of safinamide and levodopa could significantly improve motor fluctuations for PD patients in China, without compromising safety.